For Lung Cancer Patient, Targeted Therapy and Talented Team Made All the Difference

0

As the wife of a New England sportscaster, and the sister and mother of athletes, Lisa Eid understands sports metaphors. So when the 48-year-old non-smoker learned that she had stage IV lung cancer last year, she knew what her husband, Dave, meant when he said, “We need to find the Tom Brady of lung cancer specialists.”

Like the Patriots quarterback and Super Bowl MVP, the Eids needed an oncologist used to overcoming difficult situations. Someone who could handle Lisa’s advanced diagnosis because of past experience, and had colleagues who possessed similar confidence bred from previous success.

In Geoffrey Oxnard, MD, and the Lowe Center for Thoracic Oncology at Dana-Farber/Brigham and Women’s Cancer Center (DF/BWCC), the Eids have their quarterback — and their team.

lung cancer

Lisa Eid with her husband David, her son Drew and daughter Danielle at a 5K run/walk. Drew placed 11th in the race.

Lung cancer is diagnosed as one of two major types: small cell and non-small cell. Now advances in precision cancer medicine have enabled physician-scientists to uncover specific genetic mutations at the molecular level which drive the disease. Testing the DNA from patients’ tumors for these mutations, oncologists can provide targeted therapy – often in the form of first-line oral drugs – that offers better results with fewer side effects than standard chemotherapy infusions.

For Eid, a specific mutation in the ROS1 gene was the culprit. She began targeted therapy with the drug crizotinib just before Thanksgiving 2014; soon, her tumors shrank and quality of life improved. In fact, the mother of two teenagers felt so good on her daily regimen of pills that many people assumed she was done with active treatment.

“I’d be at the hockey rink or basketball court watching my kids, or in line at the grocery store, and people would say, ‘You look great; when did you get better?’” says Eid, who lives outside Portland, Maine. “I became a walking advertisement for targeted therapy.”

lung cancer, lisa eid

Lisa with her son, Drew, and daughter, Danielle, at a hockey development camp.

Oxnard says responses like Eids’ are the result of two developments. In 2004 physician-scientists led by Pasi Jänne, MD, PhD, director of Dana-Farber’s Lowe Center, identified that EGFR mutations found in lung cancer cause tumors to be sensitive to EGFR-targeted therapies. In the decade since, scientists have uncovered a variety of genetic alterations and targeted therapies that offer more specific, effective treatment against each patient’s individual cancer.

“Every lung cancer patient at the Lowe Center receives genetic testing of his or her tumor,” says Oxnard. “In collaboration with the pathologists at Brigham and Women’s Hospital, we can offer patients a range of tests – rapid testing for EGFR, ALK, and ROS1, or comprehensive sequencing for these and hundreds of other genes. We will soon be offering a noninvasive blood test to find mutations that lead to treatment resistance. The goal is to accelerate targeted therapy development, so even as we try one new treatment, we’re already on the search for better ones.”

That’s great news to Eid, for whom the crizotinib therapy has stopped working. She started on a new drug this October, and understands that while her cancer is not cured, it is being treated as a controlled, chronic disease.

“I have so much faith in Dr. Oxnard and his team,” says Eid. “They research and study lung cancer and it’s what they do all day, every day. If they want me on a clinical trial, I’ll do it. If they want me to switch to standard chemo, I’ll do it. I’m in the best hands.”

lisa eid, lung cancer

In August 2015, Lisa and her husband, David, visited Quebec and the Basilica de St. Anne de Beaupre.

Listen to an interview with Lisa and her husband from the 2015 WEEI/NESN Jimmy Fund Radio-Telethon.

Make An Appointment

For adults: 877-960-1562

Quick access: Appointments as soon as the next day for new adult patients

For children: 888-733-4662

All content in these blogs is provided by independent writers and does not represent the opinions or advice of Dana-Farber Cancer Institute or its partners.

Latest Tweets

Dana-Farber @danafarber
Dana-Farber clinicians have been involved in the development of several new agents approved recently for B-cell acu… https://t.co/Oo3SiY79EN
Dana-Farber @danafarber
Dana-Farber #researchers have shown that clonal hematopoiesis of indeterminate potential (CHIP) - the presence of s… https://t.co/ZlmXSeyKfZ
Dana-Farber @danafarber
CRISPR, a powerful new tool for editing the #DNA instruction manual in animals and humans, is proving a boon to… https://t.co/pCzS3riHPS

Republish our posts on your blog

Interested in sharing one of our stories on your blog? Feel free to republish this content! We just ask that you credit Dana-Farber, link to the original article, and refrain from making edits that change the original context. Questions? Email the editors at insight_blog@dfci.harvard.edu.